Rochester, Minn.-based Mayo Clinic anesthesiologist Megan Hamre, MD, presented the findings of her study at the 70th PostGraduate Assembly in Anesthesia, Dec. 9 to 13, 2016 in New York City.
The procedure was originally done under local anesthesia which caused patient discomfort. It is now done under general anesthesia with extubation during surgery to allow the patient to respond.
Dr. Hamre led researchers in examining 40 consecutive cases of thyroplasty, 39 with and one without arytenoid adduction.
Most (97.5 percent) patients received dexmedetomidine and remifentanil infusions while undergoing arytenoid adduction, while receiving continuous propofol infusions. When physicians needed patients to talk, anesthesiologists stopped dexmedetomidine and propofol temporarily maintaining patients on remifentanil.
The approach requires close communication between the anesthesiologist and the otolaryngologist to coordinate the sedation.
Although the three anesthetics are the most commonly used, they’ve never been studied together. Dr. Hamre claims they’re safe when used simultaneously. No significant adverse events occurred during hospital stays.
Dr. Hamre noted that additional prospective data would validate the findings.
More articles on anesthesia:
The state of anesthesia use in total knee replacement: 4 study insights
ProCare Pain Solutions to present at the American Academy of Pain Medicine 33rd Annual Meeting
Clinical Genomics participates in Fortified Provider Network, MultiPlan
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
